A5082176816- Dysphagia Assessment and Management
- Botulinum Toxin and Related Neurological Disorders
- Voice and Speech Disorders
- Tracheal and airway disorders
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Multiple Sclerosis Research Studies
- Esophageal and GI Pathology
- Child Nutrition and Feeding Issues
- Transcranial Magnetic Stimulation Studies
- Mitochondrial Function and Pathology
- Stroke Rehabilitation and Recovery
- Head and Neck Surgical Oncology
- Pain Mechanisms and Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Vestibular and auditory disorders
- Neurogenetic and Muscular Disorders Research
- Restless Legs Syndrome Research
- Cerebral Palsy and Movement Disorders
- Amyotrophic Lateral Sclerosis Research
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- Genetic and rare skin diseases.
- Parkinson's Disease Mechanisms and Treatments
- Trigeminal Neuralgia and Treatments
University of Messina
2001-2025
Ospedale Garibaldi
2013-2023
Neurological Surgery
2022
University of Padua
2000-2020
University of Catania
1998-2017
Fondazione IRCCS Istituto Neurologico Carlo Besta
2017
Institute of Neurological Sciences
1999-2014
Istituti di Ricovero e Cura a Carattere Scientifico
2013
Ospedale Vincenzo Cervello
2013
Imperial College Healthcare NHS Trust
2013
Objective: To evaluate the efficacy of botulinum neurotoxin type A (BoNT/A) for severe oro-pharyngeal dysphagia associated with multiple sclerosis (MS). Patients and methods: BoNT/A was injected percutaneously into hyperactive cricopharyngeal muscle 14 dysphagic MS patients under electromyographic control. were evaluated by videofluoroscopic examinations Penetration/Aspiration Scale (PAS), at week 1, 4, 12, 16, 18, 24 after injection. Results: All showed a significant improvement in all...
Background and Aims: Neurogenic dysphagia linked to failed relaxation of the upper esophageal sphincter (UES) can be treated by injecting botulinum toxin (BTX) into cricopharyngeal (CP) muscle. We compared effects this treatment in different neurological disorders with dysphagia, evaluate its efficacy over time including response a second injection. Materials Methods: Sixty-seven patients neurogenic associated incomplete or absent opening UES (24 brainstem hemispheric stroke, 21 parkinsonian...
Background: Sialorrhoea and drooling are disabling manifestations of different neurological disorders. The aim this study was to evaluate the effects botulinum neurotoxin type A (BoNT/A) injection on hypersalivation in 90 patients with diseases aetiologies, define minimum number injected salivary glands reduce sialorrhoea. Determining that need be engaged order have a significant reduction may very useful for establishing total dosage BoNT/A considered effective treatment hypersalivation....
Pain represents a common symptom of several diseases and is often associated with reduction in rehabilitation outcomes recovery. The effectiveness pain alleviation by botulinum toxin has been recently demonstrated. We searched PubMed the papers about this topic published last ten years, we selected clinical trials, guidelines, meta-analyses, reviews, systematic reviews. used different approaches: multiperspective presentation, lexical evaluation, review. review was only performed for...